Fundraising FoxPulseSight Therapeutics
2 known investors
Find your way into PulseSight Therapeutics
Sign up to find every way you can get introduced to PulseSight Therapeutics
- Your email: who you already know at PulseSight Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the PulseSight Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
PulseSight Therapeutics develops non-viral, plasmid-based gene therapies delivered via a proprietary electro-transfection system into the ciliary muscle to treat severe retinal diseases causing blindness. Its lead programs target late-stage dry AMD/geographic atrophy and wet AMD, with prior Phase 1/2 studies conducted in Europe and the USA.
Investors · 2
How we know: the company's own site · funding news · Not right? Tell us
How we know: Pureos Bioventures's portfolio page · the company's own site · a partner's Signal profile · funding news · pharmafile.com · Not right? Tell us
Funding
SEC filings, press & company announcementsSource: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does PulseSight Therapeutics do?
- PulseSight Therapeutics develops non-viral, plasmid-based gene therapies delivered via a proprietary electro-transfection system into the ciliary muscle to treat severe retinal diseases causing blindness. Its lead programs target late-stage dry AMD/geographic atrophy and wet AMD, with prior Phase 1/2 studies conducted in Europe and the USA.
- Who are PulseSight Therapeutics's investors?
- PulseSight Therapeutics's investors include +ND Capital, Pureos Bioventures.